Antimicrobials, drug discovery, and genome mining

Applied Microbiology and Biotechnology

Volumn 97, Issue 3, 2013, Pages 969-978

  Scheffler, R J ^a   Colmer, S ^a   Tynan, H ^a   Demain, A L ^a   Gullo, V P ^a  

^a DREW UNIVERSITY   (United States)

Author keywords

Antibiotics; Discovery; Genome mining; MRSA; Targets

Indexed keywords

DISCOVERY; DRUG DISCOVERY; GENOME MINING; GENOME SEQUENCING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL DISEASE; MRSA; PHARMACEUTICAL COMPANY; STAPHYLOCOCCUS AUREUS;

BACTERIA; GENES; TARGETS;

ANTIBIOTICS;

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; METACYCLINE; METICILLIN; NONRIBOSOMAL PEPTIDE SYNTHETASE; PENICILLIN DERIVATIVE; POLYKETIDE SYNTHASE; RHIZOXIN; SALINOSPORAMIDE K; UNCLASSIFIED DRUG;

ANTIBIOTICS; ANTIMICROBIAL ACTIVITY; BACTERIUM; DISEASE RESISTANCE; DISEASE TREATMENT; DRUG; GENOME; HOST-PATHOGEN INTERACTION; PHARMACEUTICAL INDUSTRY;

ACTINOBACTERIA; ANTIPROLIFERATIVE ACTIVITY; BIOINFORMATICS; BIOLOGICAL ACTIVITY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; FUNGUS; GENE CLUSTER; GENE INACTIVATION; GENE SEQUENCE; GENETIC PROCEDURES; GENOME MINING; HETEROLOGOUS EXPRESSION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PSEUDOMONAS FLUORESCENS; REVIEW; SILENT GENE; STREPTOMYCES AMBOFACIENS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; COMPUTATIONAL BIOLOGY; DATA MINING; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; GENOMICS; HUMANS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84874118804     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4609-8     Document Type: Review

References (36)

1. Infectious Disease Society of America (2004) Bad bugs, no drugs: as antibiotic discovery stagnates. a public health crisis brews. pp. 1-35 http://www.fda.gov/ohrms/dockets/dockets/04s0233/04s-0233-c000005-03-IDSA-vol1. pdf
2. ScienceDaily (2010) Mining bacterial genome reveals valuable "hidden" drugs. Aug. 2. http://www.sciencedaily.com/releases/2010/08/ 100801201329.htm-search-containment.html
3. CDC (2012) CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). http://www.cdc.gov/HAI/ settings/lab/vrsa
4. Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8:557-563
5. Bergmann S, Shümann J, Scherlach K, Lange C, Brakhage AA, Hertweck C (2007) Genomics-driven discovery of PKS-NPRS hybrid metabolites from Aspergillus nidulans. Nat Chem Biol 3:213-217
6. Bok JW, Hoffmeister D, Maggio-Hall LA, Murillo R, Glasner JD, Keller NP (2006) Genomic mining for Aspergillus natural products. Chem Biol 13:1-7
7. Brakhage AA, Schroeckh V (2011) Fungal secondary metabolites - strategies to activate silent gene clusters. Fungal Genet Biol 48:15-22
8. Challis GL, Ravel J (2000) Coelichelin, a new peptide siderophore encoded by the Streptomyces coelicolor genome: structure prediction from the sequence of its non-ribosomal peptide synthetase. FEMS Microbiol Lett 187:111-114
9. Challis GL (2008) Mining microbial genomes for new natural products and biosynthetic pathways. Microbiology 154:1555-1569
10. Chiang Y, Szewczyk E, Nayak T, Davidson AD, Sanchez JF, Lo H, Ho W, Simityan H, Kuo E, Praseuth A, Watanabe K, Oakley BR, Wang CCC (2008) Molecular genetic mining of the Aspergillus secondary metabolome: discovery of the emericellamide biosynthetic pathway. Chem Biol 15:527-532
11. Christoffersen RE (2006) Antibiotics - an investment worth making? Nat Biotechnol 24:1512-1514
12. Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3:541-548
13. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2006) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53-59
14. Demain AL, Spizek J (2012) The antibiotic crisis. In: Tegos G, Mylonakis E (eds) Antimicrobial drug discovery: emerging strategies. CAB International, Wallingford, UK, pp 26-43
15. Fox JL (2006) The business of developing antibacterials. Nat Biotechnol 24:1521-1528
16. Gross H, Stockwell VO, Henkels MD, Nowak-Thompson B, Loper JE, Gerwick WH (2007) The genomisotopic approach: a systematic method to isolate products of orphan biosynthetic gene clusters. Chem Biol 14:53-63
17. Gross H (2007) Strategies to unravel the function of orphan biosynthesis pathways: recent examples and future prospects. Appl Microbiol Biotechnol 75:267-277
18. Gross H (2009) Genomic mining - a concept for the discovery of new bioactive natural products. Curr Opin Drug Discov Devel 12:207-219
19. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ (2010) Challenges of antibacterial discovery revisited. Ann NY Acad Sci 1213:5-19
20. Henry C (2005) Genome mining hits pay dirt: DNA sequencing guides discovery and isolation of microbial natural product. Chem Eng News. http://pubs.acs.org/cen/news/83/i38/8338notw8.html
21. Laureti L, Song L, Huang S, Corre C, Leblond P, Challis GL, Aigle B (2011) Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens. Proc Natl Acad Sci USA 108:6258-6263
22. Lautru S, Deeth RJ, Bailey LM, Challis GL (2005) Discovery of a new peptide natural product by Streptomyces coelicolor genome mining. Nat Chem Biol 1:265-269
23. Lin X, Hopson R, Cane DE (2006) Genome mining in Streptomyces coelicolor: molecular cloning and characterization of a new sequiterpene synthase. J Amer Chem Soc 128:6022-6023
24. Livermore DM (2000) Antibiotic resistance in staphylococci. Int J Antimicrob Agents 16:S3-S10
25. Morris GJ Jr (2008) Germ warfare: are we creating a new generation of superbugs? Nutrition Action Health Letter: Center for Science in the Public Interest. pp. 3-6
26. Nikolouli K, Mossialos D (2012) Bioactive compounds synthesized by non-ribosomal peptide synthetases and type-I polyketide synthases discovered through genome-mining and metagenomics. Biotechnol Lett 34:1393-1403
27. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc 6:29-40
28. Pollack A (2010) Rising threat of infections unfazed by antibiotics. New York Times. http://www.nytimes.com/2010/02/27/business/27germ.html?-r=0
29. Ratti E, Trist D (2001) Continuing evolution of the drug discovery process in the pharmaceutical industry. Pure Appl Chem 73:67-75
30. Scherlach K, Hertweck C (2006) Discovery of aspoquinolones A-D, prenylated quinoline-2-one alkaloids from Aspergillus nidulans, motivated by genome mining. Org Biomol Chem 4:3517-3520
31. Sellers LJ (2003) Big pharma bails on anti-infectives research. Pharma Exec 23(12):22
32. Song L, Barona-Gomez F, Corre C, Xiang L, Udwary DW, Austin MB, Noel JP, Moore BS, Challis GL (2006) Type III polyketide sythase β-ketoacyl-ACP starter unit and ethylmalonyl-CoA extender unit selectivity discovered by Streptomyces coelicolor genome mining. J Amer Chem Soc 128:14754-14755
33. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279-1286
34. Spizek J, Novotna J, Rezanka T, Demain AL (2010) Do we need new antibiotics? The search for new targets and new compounds. J Ind Microbiol Biotechnol 37:1241-1248
35. Wenzel RP (2004) The antibiotic pipeline - challenges, costs, and values. N Engl J Med 351:523-526
36. Zhang L, Kezhi Y, Zhang Y, Huang R, Bian J, Zheng C, Sun H, Chen Z, Sun N, An R, Zhao W, Zhuo Y, You J, Song Y, Yu Z, Liu Z, Yang K, Gao H, Dai H, Zhang X, Wang J, Fu C, Pei G, Liu J, Zhang S, Goodfellow M, Jiang Y, Kuai J, Zhou G, Chen X (2007) High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci USA 104:4606-4611